0.64%| Prev Close: | 31.98 |
|---|---|
| Open: | 32.05 |
| Bid: | 18.44 x 100 |
| Ask: | N/A |
| 1y Target Est: | 32.42 |
| Beta: | 1.44 |
| Next Earnings Date: | N/A |
| Day's Range: | 31.55 - 32.55 |
|---|---|
| 52wk Range: | 21.05 - 39.00 |
| Volume: | 472,949 |
| Avg Vol (3m): | 780,714 |
| Market Cap: | 3.90B |
| P/E (ttm): | N/A |
| EPS (ttm): | -0.49 |
| Div & Yield: | N/A (N/A) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Immunotherapy: Four Companies on the Verge of Cancer-Treatment Breakthroughsat Minyanville(Mon Jun 17)
- A Trio of Cancer Immunotherapy Innovatorsat Motley Fool(Sat Jun 15)
- SGEN Starts Adcetris Phase I/II StudyZacks(Tue Jun 11)
- Acadia Pharmaceuticals Soars On Hedge Fund Investmentat Motley Fool(Tue Jun 11)
- Seattle Genetics Announces Initiation of Phase 1/2 Trial of ADCETRIS® (Brentuximab Vedotin) in Combination with Bendamustine for Hodgkin Lymphoma Patients after Initial RelapseBusiness Wire(Mon Jun 10)
- 3 Pharmaceuticals With Strong Potentialat Seeking Alpha(Wed Jun 5)
- MCO, MSFT & SGEN - Outperforming, Cash-Rich Stocksat TheStreet(Mon Jun 3)
- Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Frontline HL and MTCL Clinical Development Programs and Antibody-Drug Conjugate (ADC) Collaborator Data at ASCO Annual MeetingBusiness Wire(Sun Jun 2)
- StockCall Study on ELN, CYH, ALR, CBST, and SGENAccesswire(Fri May 31)
- Seattle Genetics to Present at Upcoming Investor ConferencesBusiness Wire(Wed May 29)
- SEATTLE GENETICS INC /WA Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersEDGAR Online(Wed May 22)
- Hodgkin Lymphoma: The Top Secret Strategy Of Seattle Genetics Revealedat Seeking Alpha(Wed May 22)
- Seattle Genetics Inc. Presents at UBS Global Healthcare Conference, May-21-2013 11:30 AMat Seeking Alpha(Tue May 21)
- Tackling Cancer: Leukemia's Biggest Current and Upcoming Playersat Motley Fool(Sun May 19)
- A Portfolio Construction Strategy with an Emphasis on High-Innovation, Breakthrough Biotech and Pharmaceutical CompaniesWall Street Transcript(Thu May 16)
Press Releases
- Seattle Genetics Announces Initiation of Phase 1/2 Trial of ADCETRIS® (Brentuximab Vedotin) in Combination with Bendamustine for Hodgkin Lymphoma Patients after Initial RelapseBusiness Wire(Mon Jun 10)
- StockCall Study on ELN, CYH, ALR, CBST, and SGENAccesswire(Fri May 31)
- StockCall Study on Gilead Sciences, NPS Pharma, InterMune, Seattle Genetics, and Halozyme TherapeuticsAccesswire(Wed Apr 24)
Must Read
- Beverage group: Banning food stamps from being used for sugary drinks won't make US healthierThe Canadian Press(1969-12-31T18:59:59GMT-05:00)
- Dish abandons Sprint bid for now to focus on ClearwireReuters(1969-12-31T18:59:59GMT-05:00)
- Verizon CFO says U.S. wireless carrier looking at potential entry into CanadaThe Canadian Press(1969-12-31T18:59:59GMT-05:00)
- Hudson's Bay Company names Bonnie Brooks to vice-chairmanThe Canadian Press(1969-12-31T18:59:59GMT-05:00)
- RBC analyst says BlackBerry should be profitable this fiscal yearThe Canadian Press(1969-12-31T18:59:59GMT-05:00)